Amazon Studios Orders Fourth Season of the Award-Winning Comedy The Marvelous Mrs. Maisel
13.12.2019 02:10:00 EET | Business Wire | Press release
(NASDAQ:AMZN) – Amazon Studios announced today that it has ordered a fourth season of the Emmy and Golden Globe-Award winning comedy The Marvelous Mrs. Maisel. The third season premiered Friday, Dec. 6 on Amazon Prime Video in more than 200 countries and territories worldwide. The Marvelous Mrs. Maisel received two Golden Globe nominations this week, for Best Television Series, Musical or Comedy, and for star Rachel Brosnahan for Best Performance by an Actress in a Series, Musical or Comedy.
“We were thrilled to hear that for the fourth time, we do not have to pack up and vacate the premises,” said Creator and Executive Producer Amy Sherman-Palladino and Executive Producer Daniel Palladino. “We’d like to thank Amazon for all their faith and support, their partnership and enthusiasm, and for letting us hang with our favorite people, the cast and crew of Maisel, for a little while longer.”
“The Marvelous Mrs. Maisel has been a worldwide phenomenon, and Season 3 has been no exception, with the series’ most watched opening weekend ever. We’re so happy that our Prime Video customers will get to see Midge’s story continue in Season 4,” said Jennifer Salke, Head of Amazon Studios. “Amy and Dan have created such funny, charming, relatable characters, all with their inimitable wit and eye for detail, and our customers around the world will be delighted to have another season in the world of The Marvelous Mrs. Maisel.”
In Season Three of The Marvelous Mrs. Maisel, Midge and Susie discover that life on tour with Shy is glamorous but humbling, and they learn a lesson about show business they’ll never forget. Joel struggles to support Midge while pursuing his own dreams, Abe embraces a new mission and Rose learns she has talents of her own.
The Marvelous Mrs. Maisel is the winner of sixteen Emmy Awards including Outstanding Comedy series, three Golden Globes including Best TV Series—Comedy, five Critics’ Choice Awards including Best Comedy Series, two PGA Awards, a WGA Award, and a Peabody Award.
The Marvelous Mrs. Maisel stars Emmy and Golden Globe winner Rachel Brosnahan, Golden Globe winner and four-time Emmy winner Tony Shalhoub, two-time Emmy winner Alex Borstein, Emmy nominee Marin Hinkle, Michael Zegen, Kevin Pollak, Caroline Aaron and Emmy winner Jane Lynch.
Prime members can stream The Marvelous Mrs. Maisel at www.amazon.com/Maisel Members can also download the series to mobile devices for offline viewing at no additional cost to their membership. The series is a global release and available on PrimeVideo.com for Prime Video members in more than 200 countries and territories. Watch where and when you want with the Prime Video app on your smart TV, mobile device, Fire TV, Fire tablet, Apple TV, Chromecast, game consoles, Comcast X1 or from the web. For a complete list of compatible devices, visit amazon.com/howtostream. Customers who are not already Prime members can sign up for a free trial at www.amazon.com/prime.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191212005869/en/
Contact information
Amazon.com, Inc.
Media Hotline
Amazon-pr@amazon.com
www.amazon.com/pr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom